GBM in disease context refers to glioblastoma (historically glioblastoma multiforme), an aggressive primary brain malignancy with poor prognosis. Symptoms are often initially nonspecific and can progress rapidly as tumor burden increases. Multimodal treatment typically includes surgery, radiation, and chemotherapy.
Diakonos Oncology's Phase 2 glioblastoma trial of DOC1021 continues after independent safety review found no concerns. The company will present clinical data on the dendritic cell therapy at AACR and AAN conferences in April 2026.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Researchers have developed a remote-controlled CAR T-cell therapy that can be switched off on demand using venetoclax, while new engineering strategies aim to overcome barriers in treating glioblastoma and other solid tumors.
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
The FDA has approved Novocure's Optune Pax device for locally advanced pancreatic cancer, marking the first new treatment for this patient group in decades. A trial of 571 patients showed a two-month improvement in overall survival when combined with chemotherapy.
The FDA approved Novocure's Optune Pax device for locally advanced pancreatic cancer treatment alongside chemotherapy, marking the first new treatment option in this indication since 1996. Phase III trial data showed statistically significant survival improvement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07416188 |
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma |
RECRUITING | PHASE1/PHASE2 |
| NCT07387666 |
Imaging Acetadote Metabolism in Glioblastoma |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07384884 |
Surgery and Laser Interstitial Thermal Therapy for Bilateral Glioblastomas |
NOT_YET_RECRUITING | NA |
| NCT07326566 |
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII |
RECRUITING | PHASE2 |
| NCT07274787 |
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma |
NOT_YET_RECRUITING | NA |
| NCT07225621 |
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma |
RECRUITING | PHASE2 |
| NCT07179328 |
Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy |
RECRUITING | PHASE1 |
| NCT06914700 |
A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators: |
COMPLETED | |
| NCT06855628 |
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM) |
SUSPENDED | PHASE2 |
| NCT06806228 |
Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard Treatment of Glioblastoma/Diffuse Midline Glioma and Response to Treatment (Regardless of Mutation Status) |
SUSPENDED | PHASE1 |
